News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
754,972 Results
Type
Article (44491)
Company Profile (265)
Press Release (710203)
Multimedia
Podcasts (135)
Webinars (23)
Section
Business (211275)
Career Advice (2120)
Deals (36872)
Drug Delivery (148)
Drug Development (83666)
Employer Resources (176)
FDA (16971)
Job Trends (15559)
News (358050)
Policy (34160)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (3)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (6)
Academia (2654)
Accelerated approval (55)
ADA (44)
Adcomms (31)
Allergies (199)
Alliances (51592)
ALS (231)
Alzheimer's disease (1869)
Antibody-drug conjugate (ADC) (540)
Approvals (17453)
Artificial intelligence (759)
ASCO (333)
Autoimmune disease (351)
Automation (64)
Bankruptcy (375)
Best Places to Work (11768)
BIO (69)
BIOSECURE Act (21)
Biosimilars (243)
Biotechnology (163)
Bladder cancer (204)
Brain cancer (79)
Breast cancer (816)
Cancer (6423)
Cardiovascular disease (522)
Career advice (1811)
Career pathing (46)
CAR-T (362)
CDC (61)
Celiac Disease (3)
Cell therapy (984)
Cervical cancer (56)
Clinical research (73192)
Collaboration (2277)
Commercialization (1)
Company closure (5)
Compensation (1532)
Complete response letters (93)
COVID-19 (2829)
CRISPR (122)
C-suite (1285)
Cystic fibrosis (162)
Data (8727)
Decentralized trials (3)
Denatured (41)
Depression (180)
Dermatology (98)
Diabetes (674)
Diagnostics (7123)
Digital health (65)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (377)
Drug pricing (222)
Drug shortages (34)
Duchenne muscular dystrophy (310)
Earnings (93980)
Editorial (71)
Employer branding (21)
Employer resources (158)
Events (123625)
Executive appointments (1165)
FDA (21064)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (22)
Frontotemporal dementia (35)
Funding (1882)
Gene editing (254)
Generative AI (65)
Gene therapy (775)
GLP-1 (1148)
Government (4898)
Grass and pollen (7)
Guidances (422)
Healthcare (19336)
Hematology (195)
HIV (90)
Huntington's disease (63)
IgA nephropathy (115)
Immunology and inflammation (317)
Immuno-oncology (109)
Indications (223)
Infectious disease (3198)
Inflammatory bowel disease (230)
Inflation Reduction Act (14)
Influenza (143)
Intellectual property (325)
Interviews (332)
IPO (16962)
IRA (57)
Job creations (4077)
Job search strategy (1502)
JPM (65)
Kidney cancer (21)
Labor market (113)
Layoffs (606)
Leadership (44)
Legal (8428)
Liver cancer (104)
Longevity (36)
Lung cancer (846)
Lymphoma (480)
Machine learning (67)
Management (62)
Manufacturing (1199)
Marketing (4)
MASH (217)
Medical affairs (1)
Medical device (14090)
Medtech (14264)
Mergers & acquisitions (21236)
Metabolic disorders (1696)
mRNA (242)
Multiple sclerosis (200)
NASH (18)
Neurodegenerative disease (469)
Neuropsychiatric disorders (115)
Neuroscience (3543)
Neurotech (1)
NextGen: Class of 2026 (6650)
Non-profit (4587)
Now hiring (83)
Obesity (785)
Opinion (324)
Ovarian cancer (244)
Pain (285)
Pancreatic cancer (356)
Parkinson's disease (396)
Partnered (37)
Patents (653)
Patient recruitment (781)
Peanut (70)
People (61990)
Pharmaceutical (69)
Pharmacy benefit managers (35)
Phase 1 (22720)
Phase 2 (32213)
Phase 3 (24107)
Pipeline (10010)
Policy (349)
Postmarket research (2661)
Preclinical (9670)
Press Release (68)
Prostate cancer (338)
Psychedelics (61)
Radiopharmaceuticals (353)
Rare diseases (1227)
Real estate (6325)
Recruiting (73)
Regulatory (26783)
Reports (57)
Research institute (2476)
Resumes & cover letters (363)
Rett syndrome (46)
RNA editing (27)
RSV (90)
Schizophrenia (193)
Series A (322)
Series B (238)
Service/supplier (11)
Sickle cell disease (125)
Special edition (28)
Spinal muscular atrophy (172)
Sponsored (49)
Startups (3801)
State (2)
Stomach cancer (19)
Supply chain (138)
Tariffs (99)
The Weekly (92)
Vaccines (1184)
Venture capital (124)
Weight loss (511)
Women's health (139)
Worklife (21)
Date
Today (62)
Last 7 days (431)
Last 30 days (2101)
Last 365 days (30860)
2026 (16722)
2025 (30670)
2024 (35712)
2023 (40626)
2022 (51797)
2021 (56325)
2020 (54788)
2019 (47394)
2018 (35767)
2017 (33134)
2016 (32661)
2015 (38614)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (807)
Alabama (93)
Alaska (7)
Arizona (374)
Arkansas (16)
Asia (42908)
Australia (6889)
California (14127)
Canada (4011)
China (1547)
Colorado (602)
Connecticut (616)
Delaware (438)
Europe (92422)
Florida (2132)
Georgia (448)
Hawaii (3)
Idaho (63)
Illinois (1176)
India (103)
Indiana (642)
Iowa (25)
Japan (616)
Kansas (136)
Kentucky (51)
Louisiana (60)
Maine (76)
Maryland (1678)
Massachusetts (10166)
Michigan (380)
Minnesota (765)
Mississippi (6)
Missouri (149)
Montana (33)
Nebraska (30)
Nevada (151)
New Hampshire (84)
New Jersey (3698)
New Mexico (31)
New York (3721)
North Carolina (1800)
North Dakota (9)
Northern California (7133)
Ohio (422)
Oklahoma (24)
Oregon (46)
Pennsylvania (2809)
Puerto Rico (31)
Rhode Island (53)
South America (1180)
South Carolina (89)
South Dakota (2)
Southern California (5609)
Tennessee (231)
Texas (2273)
United States (49948)
Utah (421)
Vermont (2)
Virginia (360)
Washington D.C. (81)
Washington State (1125)
West Virginia (4)
Wisconsin (141)
Wyoming (2)
754,972 Results for "marinus pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio
June 28, 2026
·
5 min read
Layoffs
Marinus Pharmaceuticals Lays Off 45% of Employees
The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.
November 14, 2024
·
1 min read
·
Angela Gabriel
Pharm Country
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its commitment to defending its patent portfolio amidst an Inter Partes Review (IPR) challenge of U.S. Patent 11,110,100 from Ovid Therapeutics, Inc. filed on March 26, 2024.
March 27, 2024
·
7 min read
Press Releases
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
December 30, 2024
·
11 min read
Press Releases
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
June 3, 2026
·
4 min read
Press Releases
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
June 3, 2026
·
5 min read
Pharm Country
Marinus Pharmaceuticals to Present at Upcoming March 2024 Investor Conferences
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that management will present at and participate in the following conferences in March.
February 21, 2024
·
1 min read
Press Releases
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
May 5, 2026
·
6 min read
Drug Development
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
Marinus Pharmaceuticals, Inc. today announced completion of enrollment in the global Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults.
May 17, 2024
·
7 min read
Pharm Country
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
Marinus Pharmaceuticals, Inc. today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference.
May 2, 2024
·
1 min read
1 of 75,498
Next
